Acadia Pharmaceuticals ACAD Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Neurocrine BiosciencesNBIX

$463.5M-6.0%

MapLight Therapeutics, Inc.MPLT

$5.59M—

Taysha Gene Therapies, Inc.TSHA

$19.32M+4.4%

Zevra Therapeutics, Inc.ZVRA

$1.5M-5.6%

LBR

LB Pharmaceuticals IncLBRX

$3.47M—

Rapport Therapeutics, Inc.RAPP

$11.48M+678%

FAQ

What is Acadia Pharmaceuticals's operating lease liabilities (total)?

Acadia Pharmaceuticals (ACAD) reported operating lease liabilities (total) of $73.85M in Q2 2026.

How has Acadia Pharmaceuticals's operating lease liabilities (total) changed year-over-year?

Acadia Pharmaceuticals's operating lease liabilities (total) increased by 31.2% year-over-year, from $56.29M to $73.85M.

What is the long-term trend for Acadia Pharmaceuticals's operating lease liabilities (total)?

Over 5 years (2020 to 2025), Acadia Pharmaceuticals's operating lease liabilities (total) has grown at a 1.0% compound annual growth rate (CAGR), from $49.55M to $52.19M.

What does operating lease liabilities (total) mean?

This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.